Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Insitro, Backed By Jeff Bezos, Signs Gilead Deal To Make Nash Drugs
Venture Capital

Insitro, Backed By Jeff Bezos, Signs Gilead Deal To Make Nash Drugs

by businessinsider.com posted 1month ago 9 views
Pharmaceutical giant Gilead is teaming up with Silicon Valley startup Insitro to develop better drugs for a quietly emerging disease called NASH. Short for non-alcoholic steatohepatitis, NASH can lead to liver failure and is estimated to affect some 16 million Americans. Insitro is led by the former chief computing officer of Google life-extension spinoff Calico. It has backing from top-notch tech investors like Jeff Bezos and life science firms like Verily. The three-year deal could be worth as much as $250 million for Insitro. Visit BusinessInsider.com for more stories.

In this article